Tempest Therapeutics, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission, disclosing financial results, business operations, and risk factors as of that period.

Key Highlights

  • Share count: As of March 25, 2026, the company had 14,344,034 shares of common stock, $0.001 par value per share, outstanding.
  • Market capitalization of non-affiliate float: The aggregate market value of common equity held by non-affiliates as of June 30, 2025 was approximately $30.1 million, based on a closing price of $6.80 per share.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company.
  • Asset Acquisition: The filing references an "Asset Acquisition" as a defined term and describes it as a subject of forward-looking statements, including expectations regarding benefits and expected synergies.
  • No incorporated documents: The filing states "None" under Documents Incorporated by Reference.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Act.

Tempest Therapeutics: Annual Disclosure for the Year Ended December 31, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST), a Delaware-incorporated biopharmaceutical company headquartered at 2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005, filed its Annual Report on Form 10-K covering the fiscal year ended December 31, 2025. The filing was made with the SEC under Commission File Number 001-35890. The company's common stock and Series A Junior Participating Preferred Purchase Rights are listed on The Nasdaq Stock Market LLC.

According to the filing, the company had 14,344,034 shares of common stock outstanding as of March 25, 2026. The aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $30.1 million as of June 30, 2025, calculated using a closing price of $6.80 per share on that date. The filing notes that for purposes of this calculation, all officers, directors, and stockholders the registrant has concluded are affiliates are treated as affiliates, and that "this calculation does not reflect a determination that certain holders are affiliates of the Registrant for any other purpose."

The Annual Report contains forward-looking statements, which the company cautions "involve substantial risks and uncertainties." Among the subjects addressed by those statements, according to the filing, are the Asset Acquisition, the company's new strategy, product candidate development and regulatory approval, capital requirements, and general economic and market conditions. The filing identifies these statements as the company's own and subject to its cautionary language. The report covers Part I through Part IV, including Business, Risk Factors, Management's Discussion and Analysis, Financial Statements, and executive compensation disclosures.

What Was Disclosed

Tempest Therapeutics filed its Form 10-K for fiscal year ended December 31, 2025, reporting 14,344,034 shares outstanding as of March 25, 2026, a non-affiliate float market value of approximately $30.1 million as of June 30, 2025, and its classification as a non-accelerated filer and smaller reporting company.